// App-Quantinova.ai

BSH19‐OR‐028 : Enhancer landscape in Chronic Lymphocytic Leukaemia upon BTK inhibition

Researchers

Presenter

  • A. Lambe

Principal Investigators

  • N. Papakonstantinou

  • M. Gounari

  • K. Stamatopoulos

  • E. Kostareli

Medical Centers

  • Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

  • Institute of Applied Biosciences, CERTH, Thessaloniki, Greece

Locations

  • United Kingdom

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Mitogen-activated protein kinase

  • AT-rich interactive domain 3A

  • Breakpoint Cluster Region

  • Bruton tyrosine kinase

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Ibrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved